| 1 | 15870141 | Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias. | Ann Pharmacother | 2005 Jun |
1 |
| 2 | 16953392 | Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. | Cancer Chemother Pharmacol | 2007 May |
5 |
| 3 | 17107284 | Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. | Expert Opin Investig Drugs | 2006 Dec |
1 |
| 4 | 23757212 | Irreversible neurological defects in the lower extremities after haploidentical stem cell transplantation: possible association with nelarabine. | Am J Hematol | 2013 Oct |
1 |
| 5 | 25070259 | Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line. | BMC Cancer | 2014 Jul 29 |
1 |
| 6 | 26293208 | Coma associated with nelarabine in an elderly patient with T-cell acute lymphoblastic leukemia and severe chronic renal disease. | Leuk Lymphoma | 2016 |
1 |
| 7 | 27776559 | Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. | J Hematol Oncol | 2016 Oct 24 |
4 |
| 8 | 28436707 | SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. | Cell Cycle | 2017 Jun 3 |
3 |
| 9 | 30022699 | Inhibitor selectivity of CNTs and ENTs. | Xenobiotica | 2019 Jul |
2 |
| 10 | 31335977 | High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia. | Hematol Oncol | 2019 Oct |
2 |
| 11 | 31850196 | Chidamide Enhances the Cytotoxicity of Cytarabine and Sorafenib in Acute Myeloid Leukemia Cells by Modulating H3K9me3 and Autophagy Levels. | Front Oncol | 2019 |
1 |
| 12 | 32581304 | SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine. | Commun Biol | 2020 Jun 24 |
5 |
| 13 | 33845140 | Identification of a five-gene signature of the RGS gene family with prognostic value in ovarian cancer. | Genomics | 2021 Jul |
2 |
| 14 | 34482803 | Centromere protein E as a novel biomarker and potential therapeutic target for retinoblastoma. | Bioengineered | 2021 Dec |
1 |
| 15 | 34641952 | Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells. | J Exp Clin Cancer Res | 2021 Oct 12 |
1 |
| 16 | 34825941 | Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms. | Cancer Chemother Pharmacol | 2022 Jan |
4 |
| 17 | 35439288 | Disruption of dNTPs Homeostasis by Ribonucleotide Reductase Hyperactivation Overcomes AML Differentiation Blockade. | Blood | 2022 Apr 19 |
5 |